Mayne Pharma Group Limited
(ASX:MYX) has received US Food and Drug Administration (FDA) approval for its generic version of Acticlate tablets, for the treatment of infections, including severe acne.
Following the FDA approval of doxycyline hyclate, the pharmaceutical company immediately released the tablets for commercial launch to American consumers.
Mayne Pharma says annual sales of the non-generic Acticlate tablets, generated US$250 million in the US for the 12 months to April 2017.
The company says its generic version of the drug, gives patients more choice, while it’s also more affordable.
Shares in Mayne Pharma Group Limited
(ASX:MYX) are trading 1.44 per cent lower to $1.03.
